Patent: 10,138,299
Summary for Patent: 10,138,299
| Patent Claims: | see list of patent claims |
Details for Patent 10,138,299
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Celgene Corporation, A Bristol-myers Squibb Company | ABECMA | idecabtagene vicleucel | Suspension | 125736 | March 3, 2021 | 10,138,299 | |
| Celgene Corporation, A Bristol-myers Squibb Company | ABECMA | idecabtagene vicleucel | Suspension | 125736 | April 4, 2024 | 10,138,299 | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
